Literature DB >> 9626028

Blood thrombopoietin levels in clonal thrombocytosis and reactive thrombocytosis.

J C Wang1, C Chen, A D Novetsky, S M Lichter, F Ahmed, N M Friedberg.   

Abstract

BACKGROUND: Although the distinction between clonal and reactive thrombocytosis is clinically relevant because clonal thrombocytosis has more thrombohemorragic complications, the differential diagnosis of these two entities can be difficult. Methods such as the detection of unstimulated erythroid or megakaryocyte colony growth are not readily available. Therefore, we measured blood thrombopoietin levels to determine whether these levels can be used to distinguish the two conditions. PATIENTS AND METHODS: Thrombopoietin levels were measured in 73 patients with thrombocytosis (platelet count > 500,000/microL), including 39 patients with clonal thrombocytosis (20 patients with essential thrombocythemia, 15 with agnogenic myeloid metaplasia, 1 patient with polycythemia vera, and 3 with undefined myeloproliferative disorders) and 34 patients with reactive thrombocytosis (17 with malignant tumors, 11 with inflammatory diseases, 4 with sickle cell disease, and 2 with iron deficiency anemia). Seventeen normal volunteers were used as controls.
RESULTS: Thrombopoietin levels were significantly higher (P < 0.05) in patients with clonal thrombocytosis (mean +/- SD of 555 +/- 585 pg/mL), including the subgroup with essential thrombocythemia (505 +/- 459 pg/mL), than in patients with reactive thrombocytosis (290 +/- 133 pg/mL) who had similar levels as controls (201 +/- 112 pg/mL). Thrombopoietin levels in patients with clonal thrombocytosis, including essential thrombocythemia, were not correlated with platelet counts.
CONCLUSIONS: Thrombopoietin levels may be helpful in distinguishing between clonal thrombocytosis and reactive thrombocytosis. Thrombopoietin is probably responsible for the elevated platelet counts in clonal thrombocytosis including essential thrombocythemia, but not in reactive thrombocytosis. High thrombopoietin levels in patients with clonal thrombocytosis cannot be explained solely by platelet megakaryocyte mass.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9626028     DOI: 10.1016/s0002-9343(98)00090-4

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  10 in total

Review 1.  Regulating billions of blood platelets: glycans and beyond.

Authors:  Renata Grozovsky; Silvia Giannini; Hervé Falet; Karin M Hoffmeister
Journal:  Blood       Date:  2015-09-01       Impact factor: 22.113

Review 2.  Novel mechanisms of platelet clearance and thrombopoietin regulation.

Authors:  Renata Grozovsky; Silvia Giannini; Hervé Falet; Karin M Hoffmeister
Journal:  Curr Opin Hematol       Date:  2015-09       Impact factor: 3.284

Review 3.  The pathogenesis of chronic myeloproliferative diseases.

Authors:  A Tefferi
Journal:  Int J Hematol       Date:  2001-02       Impact factor: 2.490

4.  The Ashwell-Morell receptor regulates hepatic thrombopoietin production via JAK2-STAT3 signaling.

Authors:  Renata Grozovsky; Antonija Jurak Begonja; Kaifeng Liu; Gary Visner; John H Hartwig; Hervé Falet; Karin M Hoffmeister
Journal:  Nat Med       Date:  2014-12-08       Impact factor: 53.440

Review 5.  Platelet clearance by the hepatic Ashwell-Morrell receptor: mechanisms and biological significance.

Authors:  Karin M Hoffmeister; Hervé Falet
Journal:  Thromb Res       Date:  2016-05       Impact factor: 3.944

Review 6.  Thrombocytosis: too much of a good thing?

Authors:  Andrew I Schafer
Journal:  Trans Am Clin Climatol Assoc       Date:  2002

7.  A thrombopoietin receptor antagonist is capable of depleting myelofibrosis hematopoietic stem and progenitor cells.

Authors:  Xiaoli Wang; David Haylock; Cing Siang Hu; Wioleta Kowalczyk; Tianbo Jiang; Jiajing Qiu; Goar Mosoyan; Wu He; Netonia Marshall; John Mascarenhas; Anna Tarasova; Joshua Brody; David Winkler; Ronald Hoffman
Journal:  Blood       Date:  2016-04-25       Impact factor: 22.113

Review 8.  Pathologic thrombopoiesis of rheumatoid arthritis.

Authors:  Ihsan Ertenli; Sedat Kiraz; M Akif Oztürk; Ibrahim c Haznedaroğlu; Ismail Celik; Meral Calgüneri
Journal:  Rheumatol Int       Date:  2003-02-11       Impact factor: 2.631

Review 9.  The Role of Megakaryocytes in Myelofibrosis.

Authors:  Johanna Melo-Cardenas; Anna Rita Migliaccio; John D Crispino
Journal:  Hematol Oncol Clin North Am       Date:  2021-01-11       Impact factor: 3.722

10.  Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera.

Authors:  Jerry L Spivak; Akil Merchant; Donna M Williams; Ophelia Rogers; Wanke Zhao; Amy Duffield; Linda S Resar; Alison R Moliterno; Zhizhuang J Zhao
Journal:  PLoS One       Date:  2020-06-01       Impact factor: 3.752

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.